Does elevated serum neural-antibody reactivity prove pathogenic antibodies in the brain?

An elevated serum neural-antibody panel can identify assay-level immunoglobulin reactivity, but it cannot by itself establish clinically relevant CNS autoimmunity or antibody-mediated brain injury.

Interpretation and clinical evidence

• Serum IgG/IgA reactivity to amphiphysin, dopamine D2 receptor, myelin basic protein, tubulin, and hydroxytryptamine plausibly means antibodies bound the antigens as presented in the assay. It does not prove recognition of native targets in human neural tissue.
• Broad multiplex or recombinant-antigen assays can yield low-titer false-positive signals. The absence of documented assay cutoffs, antigen preparation, cross-reactivity assessment, and independent confirmation limits confidence that every named reactivity is specific.
• Isolated serum neural-antibody positivity has limited specificity for CNS autoimmune disease. In paired-sample cohorts, serum-only positivity was associated with probable/definite autoimmune encephalitis or paraneoplastic neurologic syndromes in 31%, versus 91% for CSF-only positivity; most false-positive findings were serum-only.

Mechanistic and diagnostic implications

• Serum positivity does not show that antibodies enter the brain, are produced intrathecally, or cause neuronal dysfunction. Paired serum–CSF testing can assess CNS compartmentalization using the albumin quotient and antigen-specific antibody index, helping distinguish intrathecal synthesis from passive transfer across a disrupted blood–CSF barrier.
• Pathogenicity is best established for selected neuronal-surface antibodies when functional receptor effects and disease-relevant experimental phenotypes are demonstrated. Such evidence is not established for many of these targets.
• Confirmatory tissue-based testing plus antigen-specific assays (e.g., cell-based assay, immunoblot, or immunoprecipitation) is appropriate before assigning clinical significance. A compatible neurologic syndrome and supportive CSF, MRI, or EEG findings are essential.

Bottom line

• The results are plausible evidence of assay-detected immune binding, not proof of pathogenic antibodies within the brain. Orthogonal confirmation, paired CSF evaluation, and phenotype-consistent clinical evidence are required before inferring CNS autoimmune disease or directing treatment.